Literature DB >> 24097112

Epidemiology and importance of renal dysfunction in heart failure patients.

Gregory Giamouzis1, Andreas P Kalogeropoulos, Javed Butler, Georgios Karayannis, Vasiliki V Georgiopoulou, John Skoularigis, Filippos Triposkiadis.   

Abstract

Renal dysfunction (RD) is a frequent comorbid condition and a major determinant of outcomes in patients with heart failure (HF). It is likely that the etiology of RD in patients with HF is much more complex than we first thought and represents a matrix of independent, albeit interacting, pathophysiological pathways with effects on both the kidney and the heart that share a common denominator: aging and inflammation. Renal dysfunction in HF has been attributed, among others, to biochemical, hormonal, and hemodynamic factors, coupled with pharmacological interventions. Regardless of the cause, the development of RD or worsening renal function is common in patients with HF, and is associated with increased morbidity and mortality. There is increasing evidence, however, that transient increases in creatinine in the setting of acute HF are not prognostically important, whereas persistent deterioration does portend a higher mortality in this patient population. In addition, congestion seems to play an important role in the course of renal deterioration, and the combination of congestion and worsening renal function is the most significant clinical prognosticator in HF patients. This review aims to provide an update on the epidemiology and prognostic significance of RD in HF patients, in both the acute and the chronic setting.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24097112     DOI: 10.1007/s11897-013-0164-6

Source DB:  PubMed          Journal:  Curr Heart Fail Rep        ISSN: 1546-9530


  77 in total

1.  Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure.

Authors:  Robb D Kociol; Melissa A Greiner; Bradley G Hammill; Hemant Phatak; Gregg C Fonarow; Lesley H Curtis; Adrian F Hernandez
Journal:  Am J Cardiol       Date:  2010-04-27       Impact factor: 2.778

2.  Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure.

Authors:  Daniel E Forman; Javed Butler; Yongfei Wang; William T Abraham; Christopher M O'Connor; Stephen S Gottlieb; Evan Loh; Barry M Massie; Michael W Rich; Lynne Warner Stevenson; James B Young; Harlan M Krumholz
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

3.  Fluid loss, venous congestion, and worsening renal function in acute decompensated heart failure.

Authors:  Doron Aronson; Zaid Abassi; Eyal Allon; Andrew J Burger
Journal:  Eur J Heart Fail       Date:  2013-03-08       Impact factor: 15.534

4.  Renal insufficiency predicts the time to first appropriate defibrillator shock.

Authors:  Haitham Hreybe; Rana Ezzeddine; Maninder Bedi; William Barrington; Raveen Bazaz; Leonard I Ganz; Sandeep Jain; Ogundu Ngwu; Barry London; Samir Saba
Journal:  Am Heart J       Date:  2006-04       Impact factor: 4.749

5.  Prognostic value of serum cystatin C and N-terminal pro b-type natriuretic peptide in patients with acute heart failure.

Authors:  Juan Ignacio Pérez-Calvo; Francisco José Ruiz-Ruiz; Francisco Javier Carrasco-Sánchez; José Luis Morales-Rull; Sergio Manzano-Fernández; Luis Galisteo-Almeda; Domingo Pascual-Figal
Journal:  Eur J Intern Med       Date:  2012-06-22       Impact factor: 4.487

Review 6.  Arrhythmic complication in cardiorenal syndrome.

Authors:  Luigi Padeletti; Lisa Innocenti; Alessandro Paoletti Perini; Edoardo Gronda
Journal:  Heart Fail Rev       Date:  2011-11       Impact factor: 4.214

7.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

Review 8.  Cystatin C: a step forward in assessing kidney function and cardiovascular risk.

Authors:  Johan Lassus; Veli-Pekka Harjola
Journal:  Heart Fail Rev       Date:  2012-03       Impact factor: 4.214

9.  Renal function as a predictor of outcome in a broad spectrum of patients with heart failure.

Authors:  Hans L Hillege; Dorothea Nitsch; Marc A Pfeffer; Karl Swedberg; John J V McMurray; Salim Yusuf; Christopher B Granger; Eric L Michelson; Jan Ostergren; Jan Hein Cornel; Dick de Zeeuw; Stuart Pocock; Dirk J van Veldhuisen
Journal:  Circulation       Date:  2006-02-07       Impact factor: 29.690

10.  The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis.

Authors:  J G F Cleland; K Swedberg; F Follath; M Komajda; A Cohen-Solal; J C Aguilar; R Dietz; A Gavazzi; R Hobbs; J Korewicki; H C Madeira; V S Moiseyev; I Preda; W H van Gilst; J Widimsky; N Freemantle; Joanne Eastaugh; J Mason
Journal:  Eur Heart J       Date:  2003-03       Impact factor: 29.983

View more
  8 in total

1.  Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula.

Authors:  L Červenka; V Melenovský; Z Husková; A Sporková; M Bürgelová; P Škaroupková; S H Hwang; B D Hammock; J D Imig; J Sadowski
Journal:  Physiol Res       Date:  2015-06-05       Impact factor: 1.881

2.  Response and outcomes of cardiac resynchronization therapy in patients with renal dysfunction.

Authors:  Rita Ilhão Moreira; Pedro Silva Cunha; Pedro Rio; Manuel Nogueira da Silva; Luísa Moura Branco; Ana Galrinho; Joana Feliciano; Rui Soares; Rui Cruz Ferreira; Mário Martins Oliveira
Journal:  J Interv Card Electrophysiol       Date:  2018-02-19       Impact factor: 1.900

3.  Effect of angiotensin-converting enzyme blockade, alone or combined with blockade of soluble epoxide hydrolase, on the course of congestive heart failure and occurrence of renal dysfunction in Ren-2 transgenic hypertensive rats with aorto-caval fistula.

Authors:  P Kala; L Sedláková; P Škaroupková; L Kopkan; Z Vaňourková; M Táborský; A Nishiyama; S H Hwang; B D Hammock; J Sadowski; V Melenovský; J D Imig; L Červenka
Journal:  Physiol Res       Date:  2018-03-12       Impact factor: 1.881

4.  The impact of kidney dysfunction categorized by urinary to serum creatinine ratio on clinical outcomes in patients with heart failure.

Authors:  Yoichiro Otaki; Tetsu Watanabe; Tsuneo Konta; Harutoshi Tamura; Shigehiko Kato; Satoshi Nishiyama; Hiroki Takahashi; Takanori Arimoto; Tetsuro Shishido; Masafumi Watanabe
Journal:  Heart Vessels       Date:  2019-07-22       Impact factor: 2.037

5.  Effects of dual blockade in heart failure and renal dysfunction: Systematic review and meta-analysis.

Authors:  Alessandra Rodrigues Silva; Alexandre Goes Martini; Graziela De Luca Canto; Eliete Neves da Silva Guerra; Francisco de Assis Rocha Neves
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2019 Oct-Dec       Impact factor: 1.636

6.  Prevalence, correlates and in-hospital outcomes of kidney dysfunction in hospitalized patients with heart failure in Buea-Cameroon.

Authors:  Ahmadou Musa Jingi; Clovis Nkoke; Jean Jacques Noubiap; Denis Teuwafeu; Alex T Mambap; Cyrille Nkouonlack; Ronald Gobina; Debimeh Njume; Anastase Dzudie; Gloria Ashuntantang
Journal:  BMC Nephrol       Date:  2022-01-03       Impact factor: 2.388

7.  Echocardiographic assessment of pulmonary artery systolic pressure and outcomes in ambulatory heart failure patients.

Authors:  Andreas P Kalogeropoulos; Sarawut Siwamogsatham; Salim Hayek; Song Li; Anjan Deka; Catherine N Marti; Vasiliki V Georgiopoulou; Javed Butler
Journal:  J Am Heart Assoc       Date:  2014-02-03       Impact factor: 5.501

8.  Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants.

Authors:  Ahmed Bakillah; Fasika Tedla; Isabelle Ayoub; Devon John; Allen J Norin; M Mahmood Hussain; Clinton Brown
Journal:  Mediators Inflamm       Date:  2015-11-15       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.